Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14680063 | 1.00 | DNMT1 (0.31) | DNMT1DNMT3B | |
| SCHEMBL19033147 | 0.94 | DNMT1 (0.36) | DNMT1DNMT3B | |
| SCHEMBL10178004 | 0.93 | TOP2A (0.30) | DNMT1 | |
| SCHEMBL14937973 | 0.93 | TOP2A (0.30) | DNMT1 | |
| SCHEMBL14680042 | 0.92 | DNMT1 (0.31) | DNMT1 | |
| SCHEMBL16728029 | 0.92 | DNMT1 (0.31) | DNMT1 | |
| SCHEMBL889541 | 0.92 | CASR (0.32) | DNMT1DNMT3B | |
| SCHEMBL14680074 | 0.90 | — | — | |
| SCHEMBL16728045 | 0.90 | — | — | |
| SCHEMBL16849979 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9689035-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | LASERGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160369336-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | LASERGEN, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9399798-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | LASERGEN, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9200319-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150176074-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | LASERGEN, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150140559-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150176074-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | DNMT1 110/4885DNMT3B 36/4885 |
| US-20160369336-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | DNMT1 110/4885DNMT3B 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.